Michał Smoleński

Dr. Michał Smoleński

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MSMichał Smoleński
Michał Smoleński
BKBozena Karolewicz
Bozena Karolewicz
AGAnna M. Gołkowska
Anna M. Gołkowska
KNKarol Nartowski
Karol Nartowski
KMKatarzyna Małolepsza-Jarmołowska
Katarzyna Małolepsza-Jarmołowska
In order to overcome the limitations associated with vaginal administration of drugs, e.g., the short contact time of the drug form with the mucosa or continuous carrier wash-out, the development of new carriers for gynecological use is necessary. Furthermore, high individual anatomical and physiological variability resulting in unsatisfactory therapeutic efficacy of lipophilic active substances requires application of multicompartment drug delivery systems. This manuscript provides an up-to-date comprehensive review of the literature on emulsion-based vaginal dosage forms (EVDF) including macroemulsions, microemulsions, nanoemulsions, multiple emulsions and self-emulsifying drug delivery systems. The first part of the paper discusses (i) the influence of anatomical-physiological conditions on therapeutic efficacy of drug forms after local and systemic administration, (ii) characterization of EVDF components and the manufacturing techniques of these dosage forms and (iii) methods used to evaluate the physicochemical and pharmaceutical properties of emulsion-based vaginal dosage forms. The second part of the paper presents (iv) the results of biological and in vivo studies as well as (v) clinical evaluation of EVDF safety and therapeutic efficacy across different indications.

1 March 2017
Verified
Journal Article
Closed access
KKKatarzyna Karlowicz-Bodalska
Katarzyna Karlowicz-Bodalska
SHStanislaw Han
Stanislaw Han
JFJulia Freier
Julia Freier
MSMichał Smoleński
Michał Smoleński
ABAgnieszka Bodalska
Agnieszka Bodalska

31 July 2025 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Dorota DanielakDorota Danielak
Dorota Danielak
JPJadwiga Paszkowska
Jadwiga Paszkowska
LMLarry Martin
Larry Martin
JGJeffrey Gimbel
Jeffrey Gimbel
DFDavid Ferrizzi
David Ferrizzi
GGGrzegorz Garbacz
Grzegorz Garbacz

8 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMichał Smoleński
Michał Smoleński
Susanne MuschertSusanne Muschert
Susanne Muschert
DHDorota Haznar-Garbacz
Dorota Haznar-Garbacz
KMKatarzyna Małolepsza-Jarmołowska
Katarzyna Małolepsza-Jarmołowska
Vaginal candidiasis (VC) is an emerging global hardly treated health issue affecting millions of women worldwide. In this study, the nanoemulsion consisting of clotrimazole (CLT), rapeseed oil, Pluronic F-68, Span 80, PEG 200, and lactic acid was prepared using high-speed and high-pressure homogenization. Yielded formulations were characterized by an average droplet size of 52–56 nm, homogenous size distribution by volume, and a polydispersity index (PDI) < 0.2. The osmolality of nanoemulsions (NEs) fulfilled the recommendations of the WHO advisory note. NEs were stable throughout 28 weeks of storage. The stationary and dynamic (USP apparatus IV) pilot study of the changes of free CLT over time for NEs, as well as market cream and CLT suspension as references, were conducted. Test results of the changes in the amount of free CLT released from the encapsulated form were not coherent; in the stationary method, NEs yielded up to 27% of the released CLT dose within 5 h, while in the USP apparatus IV method, NEs released up to 10% of the CLT dose. NEs are promising carriers for vaginal drug delivery in the treatment of VC; however, further development of the final dosage form and harmonized release or dissolution testing protocols are needed.

3 April 2024 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MSMarcela Staniszewska
Marcela Staniszewska
DMDaria Myslitska
Daria Myslitska
MRMichał Romański
Michał Romański
SPSebastian Polak
Sebastian Polak
GGGrzegorz Garbacz
Grzegorz Garbacz
Dorota DanielakDorota Danielak
Dorota Danielak

20 November 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Daniel ZakowieckiDaniel Zakowiecki
Daniel Zakowiecki
PEPeter Edinger
Peter Edinger
MPMarkos Papaioannou
Markos Papaioannou
MWMichael Wagner
Michael Wagner
Tobias HessTobias Hess
Tobias Hess
DGDorota Haznar Garbacz
Dorota Haznar Garbacz
Background/Objectives: The aim of the present study was to develop lactose-free formulations of rivaroxaban, a novel oral anticoagulant used for the treatment and prevention of blood clotting. As a BCS Class II drug, rivaroxaban is characterized by poor solubility in aqueous media, posing a significant formulation challenge. Methods: To address this, phosphate-based excipients were employed to prepare both traditional single-unit dosage forms (tablets) and modern multiple-unit pellet systems (MUPS). These formulations were successfully developed and thoroughly evaluated for their physical properties and performance. Results: The resulting formulations demonstrated very good mechanical strength, including appropriate hardness and friability, alongside strong chemical stability. Their dissolution profiles met the requirements of the compendial monograph for Rivaroxaban Tablets and were comparable to those of the reference product, Xarelto® film-coated tablets. Conclusions: This study shows the potential for producing effective, stable, and patient-friendly medications that meet the needs of contemporary society, where an increasing number of individuals suffer from lactose intolerance or seek vegan-friendly alternatives.